scholarly journals Achieving Blood Pressure Control with Telmisartan and Fixed Dose Combination of Telmisartan and Hydrochlorothiazide

2016 ◽  
Vol 11 (10-11) ◽  
pp. 598-601
Author(s):  
Anja Zaletel ◽  
Polona Knavs Vrhunec ◽  
Breda Barbič-Žagar
Keyword(s):  
Blood Pressure ◽  
Blood Pressure Control ◽  
Pressure Control ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Dose Combination

HIGH-RISK HYPERTENSIVE PATIENTS: ASSESSMENT OF BLOOD PRESSURE CONTROL, ADHERENCE TO FIXED-DOSE COMBINATION TREATMENTS AND SATISFACTION: PP.5.201

2010 ◽  
Vol 28 ◽  
pp. e108
Author(s):  
MA Prieto Diaz ◽  
JA Divison Garrote ◽  
J Abellan Aleman ◽  
JL Llisterri Caro ◽  
NR Robles P&;eacute;rez-Monteoliva ◽  
...  
Keyword(s):  
Blood Pressure ◽  
High Risk ◽  
Blood Pressure Control ◽  
Pressure Control ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Hypertensive Patients ◽  
Combination Treatments ◽  
Dose Combination

scholarly journals Blood pressure control and vascular protection with a fixed-dose combination of lisinopril + amlodipine + rosuvastatin in hypertensive patients

Vessel Plus ◽  
2018 ◽  
Vol 2 (11) ◽  
pp. 37
Author(s):  
Sergey V. Nedogoda ◽  
Elena V. Chumachek ◽  
Alla A. Ledyaeva ◽  
Vera V. Tsoma ◽  
Alla S. Salasyuk ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Blood Pressure Control ◽  
Pressure Control ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Vascular Protection ◽  
Hypertensive Patients ◽  
Dose Combination

scholarly journals Fixed-dose combination of amlodipine/indapamide/perindopril arginine — a rational and safe choice for blood pressure control in actual clinical setting: data of an observational program DOKAZATEL`STVO

2020 ◽  
Vol 25 (6) ◽  
pp. 3805 ◽  
Author(s):  
J. D. Kobalava ◽  
V. V. Tolkacheva ◽  
E. A. Troitskaya ◽  
I. A. Kolesnikova ◽  
M. A. Markova
Keyword(s):  
Blood Pressure ◽  
Blood Pressure Control ◽  
Clinical Setting ◽  
Antihypertensive Agents ◽  
Pressure Control ◽  
Home Blood Pressure ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Dose Combination ◽  
Observational Program

Aim. To analyze the efficacy and tolerability of amlodipine/indapamide/perindopril arginine (Triplixam) in a subgroup of 790 people participating in the Russian observational program DOKAZATEL`STVO without use of other antihypertensive agents.Material and methods. The analysis included 790 patients with hypertension (HTN) (men — 37,9%, mean age — 60,0±10,2 years). The drug was administrated in one of 4 recommended dosages for 3 months. We assessed the dynamics of office and home blood pressure (BP) from visit 1 to visit 4 and the frequency of achieving the target BP <140/90 mm Hg in 3 months.Results. After 3 months, office systolic BP (SBP) decreased from 163,4±14,0 to 127,2±7,8 mm Hg, diastolic BP (DBP) — from 95,7±9,5 to 78,3±6,2 mm Hg (p 0,001). Home SBP in the morning decreased from 145,9±12,3 to 128,3±7,8 mm Hg, DBP — from 86,2±7,7 to 78,4±5,6 mm Hg (p<0,001). After 3 months, target office BP (<140/90 mm Hg) was achieved in 88,4% of subjects, home BP (<135/85 mm Hg) — 73%.Conclusion. The administration of Triplixam without additional antihypertensive agents results in a significant BP decrease by 36/17 mm Hg and rapid achievement of BP control in most patients. The combination is safe and well tolerated.

FIXED DOSE COMBINATION THERAPY IS ASSOCIATED WITH BETTER BLOOD PRESSURE CONTROL AND LOWER ALBUMINURIA IN REAL-LIFE COHORT DURING 7 YEARS OF FOLLOW UP. ENAH – CROATIAN RURAL STUDY

2018 ◽  
Vol 36 (Supplement 1) ◽  
pp. e169
Author(s):  
A. Jelakovic ◽  
M. Abramovic ◽  
Z. Dika ◽  
V. Domislovic ◽  
K. Djapic ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Combination Therapy ◽  
Blood Pressure Control ◽  
Real Life ◽  
Pressure Control ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Rural Study ◽  
Dose Combination

A New Fixed-Dose Combination for Added Blood Pressure Control: Telmisartan Plus Hydrochlorothiazide

2002 ◽  
Vol 30 (4) ◽  
pp. 366-379 ◽  
Author(s):  
Y Lacourcière
Keyword(s):  
Blood Pressure ◽  
Cost Effective ◽  
Pressure Control ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Angiotensin Ii Receptor Blocker ◽  
Angiotensin Ii Receptor ◽  
Wide Range ◽  
Dosing Regimens ◽  
Dose Combination

Population surveys on hypertension management reveal worrying deficiencies in the awareness and treatment of high blood pressure. Many patients with hypertension will require two or more drugs with complementary mechanisms of action (which generally have additive effects, producing greater blood pressure reductions than either agent alone) to attain the blood pressure goals specified in internationally accepted guidelines. Nevertheless, physicians are often reluctant to prescribe multiple anti-hypertensive drugs due to concerns over side-effects, inconvenient dosing regimens and costs. Fixed-dose formulations combining two agents from different classes in a single tablet should help to allay these concerns. A fixed-dose combination containing telmisartan (an angiotensin II receptor blocker) and hydrochlorothiazide (a thiazide diuretic) has recently been developed. Telmisartan/hydrochlorothiazide provides additional anti-hypertensive efficacy compared with the respective monotherapies in a wide range of patients, including black patients, requires once-daily dosing, is cost-effective, well tolerated and is associated with less potassium depletion than hydrochlorothiazide administered alone.

scholarly journals Optimization of blood pressure control, organ protection and metabolic disorders using a fixed-dose combination of lisinopril+amlodipine+rosuvastatin in hypertensive patients after COVID-19

2021 ◽  
Vol 26 (12) ◽  
pp. 4766
Author(s):  
S. V. Nedogoda ◽  
A. A. Ledyaeva ◽  
E. V. Chumachek ◽  
V. V. Tsoma ◽  
A. S. Salasyuk ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Blood Pressure Monitoring ◽  
Pressure Control ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
C Reactive Protein ◽  
Pressure Monitoring ◽  
Reactive Protein ◽  
Dose Combination ◽  
Baseline Values

Aim. To evaluate the potential of a fixed-dose combination of lisinopril+amlodipine+rosuvastatin (Equamer®) in achieving additional vascular protection in patients with hypertension and high pulse wave velocity (PWV) after severe and very severe coronavirus disease 2019 (COVID-19), complicated by bilateral multisegmental viral pneumonia, with the use of biological therapy, who had not previously received combination antihypertensive therapy.Material and methods. This 12-week open-label observational study included 30 patients with or without antihypertensive therapy. The patients underwent 24-hour blood pressure monitoring, applanation tonometry (determination of the augmentation index (AI) and central blood pressure (CBP)), PWV measurement, blood laboratory tests (lipid profile, fasting glucose, C-reactive protein, complete blood count, ferritin, fibrinogen, D-dimer, alanine aminotransferase, aspartate aminotransferase, creatinine, uric acid) before and after switch to a fixed-dose combination of lisinopril+amlodipine+rosuvastatin.Results. At baseline, the patients had an increase in office blood pressure (BP) up to 152,6/89,1 mm Hg. After prescribing a fixed-dose combination of lisinopril+amlodipine+rosuvastatin, there was a decrease in systolic blood pressure (SBP) by 15,8% and diastolic blood pressure (DBP) by 12,2%. According to 24-hour blood pressure monitoring, the decrease in SBP was 15%, DBP — by 9%, PWV — by 23,8%, AI — by 9%, CBP — by 12,4% (p<0,05 for all compared to baseline values). Vascular age (VA) was initially increased to 41,9 years with a chronological age of 35,03 years. After the end of therapy, there was a significant decrease in VA to 36,5 years, low-density lipoproteins by 46,8%, triglycerides by 16,8% and an increase in high-density lipoproteins by 10,7% (p<0,05 for all compared to baseline values). In addition, the levels of C-reactive protein, fibrinogen, D-dimer, glucose, and uric acid significantly decreased.Conclusion. The fixed-dosed combination of lisinopril+amlodipine+rosuvastatin provides better blood pressure control, improved vascular elasticity parameters (AI, PWV, CBP, decrease in VA), and also improves lipid and carbohydrate metabolism, reduces inflammation in patients with hypertension and hyperlipidemia after severe COVID-19. 

Sign in / Sign up

Export Citation Format

Share Document